SUNNYVALE, Calif., Oct. 22 /PRNewswire/ -- Biocircuits Corporation
(Nasdaq: BIOC) announced today the availability of a new test cartridge for
use on the IOS(R) system that performs a quantitative hCG test for monitoring
of difficult pregnancies.  Various market surveys indicate that office based
physicians request approximately 4.3 million of these tests per year.
    The IOS system is the first easy to use and economical system for
performing immunoassays in lower volume sites such as the physician office.
Although approximately 36,000 sites currently have the requisite moderately
complex license for performing such tests, most send the testing out to large
laboratories.
    "With the addition of the new cartridge we now have three cartridges
available and plan to file 510(k's) with the FDA for three more cartridges
over the next six months," said John Kaiser, President and CEO.  "The three
new filings that we plan to do are tests for Digoxin, Free T4 and our first
cancer marker, PSA," Mr. Kaiser further stated.
    Actual results may differ materially from the above forward-looking
statements due to a number of important factors, and will be dependent upon
the Company's ability, directly or through third parties, to successfully
manufacture and market its existing and proposed products, as well as the
timely development and regulatory approval of additional products.  These
factors are more fully discussed in the Company's most recent reports on Forms
10-K and the Company's resale Registration Statement No. 333-13673.

Link to this page: